Oxyntomodulin - Merck

Drug Profile

Oxyntomodulin - Merck

Latest Information Update: 09 Mar 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Jul 2011 Merck completes a phase I trial in Type-2 diabetes mellitus in Netherlands (NCT01373450)
  • 10 Jun 2010 Merck completes a phase I trial in Healthy volunteers in Netherlands
  • 04 May 2010 Phase-I clinical trials in Diabetes mellitus in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top